CAMP (CAMP4 Therapeutics Corporation Common Stock) Stock Analysis - News
CAMP4 Therapeutics Corporation Common Stock (CAMP) is a publicly traded Healthcare sector company. As of May 21, 2026, CAMP trades at $4.50 with a market cap of $236.78M and a P/E ratio of -1.90. CAMP moved +8.80% today. Year to date, CAMP is -24.87%; over the trailing twelve months it is +101.79%. Its 52-week range spans $1.31 to $12.30. Analyst consensus is strong buy with an average price target of $8.60. Rallies surfaces CAMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CAMP news today?
CAMP4 Therapeutics’ CMP-002 Increases Seizure Threshold, Reduces Severity in SYNGAP1 Model: CAMP4 Therapeutics reported that a single dose of its ASO candidate, CMP-002, produced a statistically significant increase in seizure threshold and reduced seizure severity in a SYNGAP1 haploinsufficient mouse model. The company plans to initiate a Phase 1/2 clinical trial in SYNGAP1-related disorder patients in the second half of 2026.
CAMP4 Therapeutics’ CMP-002 Increases Seizure Threshold, Reduces Severity in SYNGAP1 Model: CAMP4 Therapeutics reported that a single dose of its ASO candidate, CMP-002, produced a statistically significant increase in seizure threshold and reduced seizure severity in a SYNGAP1 haploinsufficient mouse model. The company plans to initiate a Phase 1/2 clinical trial in SYNGAP1-related disorder patients in the second half of 2026.
Does Rallies summarize CAMP news?
Yes. Rallies summarizes CAMP news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CAMP research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CAMP. It does not provide personalized investment advice.
